Wintech Nano
688757
CHANGFU CO.,LTD
871396
DIER CHEMICAL
831304
4
CHENGUANG MEDICAL
430300
5
TLC
873576
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | -10.93%176.47M | -10.21%106.25M | 16.04%49.62M | 25.53%255.01M | 1.51%198.12M | 13.48%118.32M | 3.10%42.76M | -35.79%203.15M | 58.58%195.18M | 4.83%104.27M |
Operating revenue | -10.93%176.47M | -10.21%106.25M | 16.04%49.62M | 25.53%255.01M | 1.51%198.12M | 13.48%118.32M | 3.10%42.76M | -35.79%203.15M | 58.58%195.18M | 4.83%104.27M |
Total operating cost | -5.63%212M | 2.85%129.77M | 28.55%62.41M | 43.67%315.98M | 19.43%224.65M | 23.27%126.18M | 6.54%48.55M | -25.54%219.93M | 72.70%188.1M | 17.36%102.36M |
Operating cost | -1.29%162.11M | 5.05%96.81M | 45.75%47.47M | 46.98%235.49M | 15.07%164.22M | 20.66%92.15M | -11.12%32.57M | -36.48%160.22M | 74.08%142.71M | 10.09%76.38M |
Operating tax surcharges | 326.43%271.67K | 1,935.44%202.04K | -36.35%119.96K | 13.58%1.26M | -42.32%63.71K | -111.42%-11.01K | 1,783.38%188.45K | -38.45%1.11M | -55.15%110.45K | -43.80%96.42K |
Operating expense | 6.87%10.56M | 17.54%6.69M | -2.27%1.78M | 50.91%21.98M | 139.54%9.88M | 80.80%5.7M | 8.85%1.82M | 25.86%14.56M | -19.63%4.12M | 2.68%3.15M |
Administration expense | -21.77%20M | -20.73%12.99M | -34.36%5.86M | -5.61%24.26M | -1.99%25.56M | 13.84%16.39M | 195.33%8.93M | 101.26%25.7M | 213.46%26.08M | 159.61%14.4M |
Financial expense | 9.44%4.4M | -13.70%2.39M | 55.79%1.42M | 6,462.60%5.91M | 863,974.78%4.02M | 3,259.84%2.77M | 2,229.58%914.4K | -92.19%90.13K | -99.96%465.09 | -106.03%-87.6K |
-Interest expense (Financial expense) | -4.48%4.2M | -26.75%2.24M | 31.64%1.22M | 200.89%6.03M | 329.39%4.4M | 404.27%3.06M | 185.47%924.05K | -10.88%2M | -44.48%1.02M | -61.15%606.64K |
-Interest Income (Financial expense) | 51.60%-445.74K | 55.22%-306.34K | 51.33%-185.11K | 45.85%-1.32M | 43.74%-920.97K | 32.36%-684.08K | 23.53%-380.38K | -74.17%-2.43M | -102.59%-1.64M | -229.83%-1.01M |
Research and development | -29.84%14.67M | 16.42%10.69M | 39.41%5.75M | 48.39%27.07M | 38.70%20.91M | 8.98%9.18M | -1.20%4.13M | 15.30%18.24M | 26.33%15.07M | 10.91%8.43M |
Credit Impairment Loss | 77.05%-4.37M | 246.20%7.19M | 159.60%5.21M | -60.12%-25.01M | -19.64%-19.03M | -202.78%-4.92M | -69.34%2.01M | 9.54%-15.62M | -256.07%-15.9M | 225.91%4.78M |
Asset Impairment Loss | -260.56%-1.39M | -761.82%-3.39M | 382.17%1.25M | -12.43%-22.48M | 306.37%863.66K | 11.48%-393.16K | -1,770.38%-442.98K | -1,256.49%-19.99M | -744.92%-418.5K | 20.54%-444.15K |
Other net revenue | ||||||||||
Invest income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---73.92K | ---- | ---- |
Asset deal income | ---5.38K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other revenue | 18.49%5.56M | 9.53%5.1M | 877.81%7.74M | -7.57%5.28M | -17.52%4.7M | -3.91%4.66M | -82.48%791.78K | 297.78%5.71M | 1,142.44%5.69M | 2,226.45%4.85M |
Operating profit | 10.67%-35.73M | -71.83%-14.63M | 141.48%1.42M | -120.68%-103.19M | -1,027.59%-39.99M | -176.74%-8.51M | -148.88%-3.43M | -1,323.38%-46.76M | -134.35%-3.55M | 35.30%11.09M |
Add:Non operating Income | 3,051.88%4.53M | 3,051.88%4.53M | 2,011,361.54%26.15K | -100.00%2.51 | 21,432,997.01%143.6K | 22,437,671.88%143.6K | --1.3 | -97.42%232.3K | -100.00%0.67 | -100.00%0.64 |
Less:Non operating expense | -99.65%11.31K | -99.13%1.71K | --1.57K | 4,693.65%3.52M | 119,136.34%3.2M | 9,862.22%195.63K | ---- | -65.99%73.34K | -97.17%2.68K | --1.96K |
Total profit | 27.49%-31.21M | -17.96%-10.1M | 142.20%1.45M | -128.98%-106.7M | -1,112.74%-43.05M | -177.23%-8.56M | -148.89%-3.43M | -469.62%-46.6M | -134.49%-3.55M | 34.29%11.09M |
Less:Income tax cost | -58.72%-6.05M | -286.37%-1.12M | 431.85%924.95K | -83.51%-18.86M | -700.94%-3.81M | -150.62%-290.04K | -81.00%173.91K | -907.51%-10.28M | 293.35%633.91K | 416.25%572.93K |
Net profit | 35.86%-25.17M | -8.55%-8.98M | 114.47%520.99K | -141.84%-87.84M | -837.92%-39.24M | -178.68%-8.27M | -159.08%-3.6M | -366.53%-36.32M | -139.39%-4.18M | 29.09%10.52M |
Net profit from continuing operation | ---- | ---- | ---- | -141.84%-87.84M | ---- | ---- | ---- | -366.53%-36.32M | ---- | ---- |
Net profit of parent company owners | 35.86%-25.17M | -8.55%-8.98M | 114.47%520.99K | -141.84%-87.84M | -837.92%-39.24M | -178.68%-8.27M | -159.08%-3.6M | -366.53%-36.32M | -139.39%-4.18M | 29.09%10.52M |
Earning per share | ||||||||||
Basic earning per share | 36.00%-0.16 | -20.00%-0.06 | 114.91%0.0034 | -124.00%-0.56 | -525.00%-0.25 | -171.43%-0.05 | -138.00%-0.0228 | -278.57%-0.25 | -133.33%-0.04 | -12.50%0.07 |
Diluted earning per share | 36.00%-0.16 | -20.00%-0.06 | 114.91%0.0034 | -124.00%-0.56 | -525.00%-0.25 | -171.43%-0.05 | -138.00%-0.0228 | -278.57%-0.25 | -133.33%-0.04 | -12.50%0.07 |
Other composite income | ||||||||||
Total composite income | 35.86%-25.17M | -8.55%-8.98M | 114.47%520.99K | -141.84%-87.84M | -837.92%-39.24M | -178.68%-8.27M | -159.08%-3.6M | -366.53%-36.32M | -139.39%-4.18M | 29.09%10.52M |
Total composite income of parent company owners | 35.86%-25.17M | -8.55%-8.98M | 114.47%520.99K | -141.84%-87.84M | -837.92%-39.24M | -178.68%-8.27M | -159.08%-3.6M | -366.53%-36.32M | -139.39%-4.18M | 29.09%10.52M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion with explanatory notes | -- | -- |
Auditor | -- | -- | -- | ZTE Accounting firm (Special General Partnership) | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.